Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Long

Showing results (281-290 of 703) with videos related to

Pageof 71
Sort By:
Journal for Immunotherapy of Cancer|May 8, 2021
Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disordersLauren J Brown, Alison Weppler, Prachi Bhave, et al.
Internal Medicine Journal|May 27, 2015
Ipilimumab-induced hypophysitis in melanoma patients: an Australian case seriesT Lam, M M K Chan, A N Sweeting, et al.
Annals of Surgical Oncology|February 22, 2012
Clinical and pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanomaRajmohan Murali, Lauren E Haydu, Georgina V Long, et al.
Histopathology|May 7, 2016
BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reportingHojabr Kakavand, Emily Walker, Trina Lum, et al.
Frontiers in Neurology|March 10, 2023
Case series: Immune checkpoint inhibitor-induced transverse myelitisSophie Chatterton, Shuo Xi, Jessica Xi Jia, et al.
Pigment Cell & Melanoma Research|December 6, 2014
PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trialsJason Madore, Ricardo E Vilain, Alexander M Menzies, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 19, 2022
Successful treatment of eruptive keratoacanthomas with actitretin for patients on checkpoint inhibitor immunotherapyR J Schwartz, G Ho, A Smith, et al.
European Journal of Cancer (Oxford, England : 1990)|March 26, 2025
Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trialJohn M Kirkwood, Peter Mohr, Christoph Hoeller, et al.
Cancer|July 29, 2015
Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitorsAlexander M Menzies, James S Wilmott, Martin Drummond, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 14, 2016
Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 studyG V Long, V Atkinson, P A Ascierto, et al.
Pageof 71

Showing results (281-290 of 703) with videos related to

Sort By:
Pageof 71
Journal for Immunotherapy of Cancer|May 8, 2021
Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disordersLauren J Brown, Alison Weppler, Prachi Bhave, et al.
Internal Medicine Journal|May 27, 2015
Ipilimumab-induced hypophysitis in melanoma patients: an Australian case seriesT Lam, M M K Chan, A N Sweeting, et al.
Annals of Surgical Oncology|February 22, 2012
Clinical and pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanomaRajmohan Murali, Lauren E Haydu, Georgina V Long, et al.
Histopathology|May 7, 2016
BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reportingHojabr Kakavand, Emily Walker, Trina Lum, et al.
Frontiers in Neurology|March 10, 2023
Case series: Immune checkpoint inhibitor-induced transverse myelitisSophie Chatterton, Shuo Xi, Jessica Xi Jia, et al.
Pigment Cell & Melanoma Research|December 6, 2014
PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trialsJason Madore, Ricardo E Vilain, Alexander M Menzies, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 19, 2022
Successful treatment of eruptive keratoacanthomas with actitretin for patients on checkpoint inhibitor immunotherapyR J Schwartz, G Ho, A Smith, et al.
European Journal of Cancer (Oxford, England : 1990)|March 26, 2025
Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trialJohn M Kirkwood, Peter Mohr, Christoph Hoeller, et al.
Cancer|July 29, 2015
Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitorsAlexander M Menzies, James S Wilmott, Martin Drummond, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 14, 2016
Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 studyG V Long, V Atkinson, P A Ascierto, et al.
Pageof 71